Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC

Phase 3

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: TPF neoadjuvant chemotherapy
Drug: Concurrent nimotuzumab during radiotherapy
Drug: Concurrent chemotherapy with cisplatin during radiotherapy
Radiation: Radical radiotherapy

First Posted Date: 2013-12-16

Last Posted Date: 2019-04-10

Lead Sponsor: Fudan University

Target Recruit Count: 160

Registration Number: NCT02012062

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

A Trial of Robotic-assisted Versus Laparoscopic Abdominoperineal Resection for Treating Low Rectal Cancer

Not Applicable

Completed

Conditions: Rectal Cancer

Interventions: Procedure: Robotic-assisted resection.
Procedure: Laparoscopic resection

First Posted Date: 2013-11-15

Last Posted Date: 2021-03-09

Lead Sponsor: Fudan University

Target Recruit Count: 347

Registration Number: NCT01985698

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

The Effect of Chronic Anemia on Safety Period of Tracheal Intubation in Gynecology Patients

Not Applicable

Completed

Conditions: Chronic Anemia

Interventions: Biological: pre-oxygen

First Posted Date: 2013-10-24

Last Posted Date: 2013-10-24

Lead Sponsor: Fudan University

Target Recruit Count: 45

Registration Number: NCT01968525

Locations: 🇨🇳
Fudan university, Shanghai, Shanghai, China

A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC

Phase 2

Conditions: Gastric Cancer

Interventions: Drug: Docetaxol
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2013-10-16

Last Posted Date: 2013-10-16

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT01963702

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery

Phase 3

Conditions: Hepatocellular Carcinoma
Recurrence

Interventions: Drug: Lamivudine
Drug: Aspirin

First Posted Date: 2013-09-06

Last Posted Date: 2019-08-05

Lead Sponsor: Fudan University

Target Recruit Count: 112

Registration Number: NCT01936233

Locations: 🇨🇳
Liver Cancer Institute, Shanghai, Shanghai, China

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Drug: aromatase Inhibitors (AIs)

First Posted Date: 2013-08-16

Last Posted Date: 2013-08-16

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT01924078

Locations: 🇨🇳
FUSCC, Shanghai, Shanghai, China

Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL

Phase 2

Conditions: Non-Hodgkin Lymphoma
Hepatitis B Reactivation

Interventions: Drug: Entecavir
Drug: Lamivudine

First Posted Date: 2013-08-02

Last Posted Date: 2013-08-02

Lead Sponsor: Fudan University

Target Recruit Count: 82

Registration Number: NCT01914744

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Dose-adjusted EPOCH-R in MYC Positive DLBCL

Phase 2

Terminated

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: DA-EPOCH-R

First Posted Date: 2013-08-02

Last Posted Date: 2014-08-20

Lead Sponsor: Fudan University

Target Recruit Count: 26

Registration Number: NCT01914718

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE

Phase 2

Conditions: Vomiting
Nausea
Metastatic Liver Cancer

Interventions: Device: acupoint electric stimulation
Drug: tropisetron

First Posted Date: 2013-07-10

Last Posted Date: 2013-07-10

Lead Sponsor: Fudan University

Target Recruit Count: 74

Registration Number: NCT01895010

Locations: 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China

Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study

Conditions: Radiotherapy
Nasopharyngeal Carcinoma
Cerebral Radiation Necrosis
MRI

Interventions: Drug: GM1

First Posted Date: 2013-06-24

Last Posted Date: 2014-01-07

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT01884987

Locations: 🇨🇳
Shanghai Cancer Center, Fudan University, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy